Brain region central to placebo effect identifiedJuly 19, 2007
Researchers have pinpointed a brain region central to the machinery of the placebo effect-the often controversial phenomenon in which a person's belief in the efficacy of a treatment such as a painkilling drug influences its effect.
The researchers said their findings with human subjects offer the potential of measuring the placebo effect and even modulating it for therapeutic purposes. They also said their findings could enable measurements of brain function that "would help determine dysfunctions in cerebral mechanisms that may impair recovery across a number of conditions."
Jon-Kar Zubieta and colleagues published their findings in the July 19, 2007, issue of the journal Neuron, published by Cell Press.
Their studies concentrated on a brain area known as the nucleus accumbens (NAC), a region deep in the brain, known to play a role in expectation of reward. Earlier studies had hinted at involvement of the NAC in the placebo effect, but the nature of that role was unknown, said the researchers.
In their experiments, the researchers told volunteers that they were testing the effects of a new pain-killing drug and that the subjects might receive the drug or a placebo. However, in the experiments, the researchers gave only a placebo injection of a salt solution. The experiments involved asking the subjects to rate their expectation of the pain-killing effects of the "drug" and also the level of pain relief with or without the "drug" that they felt from a moderately painful injection of salt solution into their jaw muscle.
In one set of experiments, the researchers used a molecular tracer scanning technique known as Positron Emission Spectroscopy to measure release from the NAC of the neurotransmitter dopamine-a chemical trigger of the brain's reward response. They found that the greater subjects' anticipation of the pain-killing benefit of the placebo, the greater the dopamine release from the NAC. Also, subjects who reported greater relief from the placebo when they did experience pain showed greater NAC activity when they received the placebo before the pain.
In separate experiments, the researchers studied whether activation of subjects' NAC during reward processing correlated with the magnitude of their placebo effect. They told subjects to expect monetary rewards of different amounts, as their brains were scanned using functional magnetic resonance imaging. The researchers found that the people who showed greater activation of the NAC during this reward-expectation task also showed a greater anticipation of effectiveness of a placebo.
The researchers concluded that "These findings are consistent with the hypothesis that this system is involved in the encoding of the 'incentive value' of the placebo, possibly acting as a gate or permissive system for the formation of placebo effects."
They wrote that "The placebo effect then emerges as a resiliency mechanism with broad implications that, given its activation of specific circuits and mechanisms, can be both examined and modulated for therapeutic purposes."
Related Placebo Current Events and Placebo News Articles
Placebo effects in women are boosted by vasopressin
A new study in the current issue of Biological Psychiatry suggests that women are particularly susceptible to the pain-relieving placebo effect of vasopressin.
Cognitive-behavioral therapy may help reduce memory problems in cancer survivors who have received chemotherapy
A new analysis indicates that a type of psychotherapy delivered by videoconference may help prevent some of the long-term memory issues caused by chemotherapy.
Black raspberry improves cardiovascular risk in metabolic syndrome
A new study shows that black raspberry extract can significantly lower a key measure of arterial stiffness-an indicator of cardiovascular disease.
Psilocybin reduces psychological pain after social exclusion
Social problems are key characteristics in psychiatric disorders and are insufficiently targeted by current treatment approaches.
Additional benefits of type 2 diabetes treatment found for non-alcoholic fatty liver disease patients
A type 2 diabetes treatment has been found to also have 'off-label' benefits for glucose control in the liver and in fatty cells known as adipose.
At-home cognitive remediation may help cognitive symptoms in multiple sclerosis
Cognitive impairment is one of the core symptoms of multiple sclerosis (MS) -- and one of its most troubling concerns for many people with the condition.
Potential first-in-class treatment is well-tolerated in patients with chronic hepatitis B
New data presented today confirms that a novel first-in-class treatment for Hepatitis B, called NVR 3-778, is well-tolerated and can reduce levels of the virus' genetic material in the body when combined with pegylated interferon after four weeks of treatment.
Investigational treatment provides hope for some chronic liver disease sufferers
A new study presented today provides hope for a new treatment in patients with primary sclerosing cholangitis, a rare condition characterised by inflammation and scarring in the bile ducts of the liver and for which there are currently no medicines.
Disappointing data for diabetes drug in the treatment of non-alcoholic fatty liver disease
New data presented today at The International Liver Congress™ 2016 in Barcelona, Spain, demonstrates that the drug sitagliptin - more commonly used to treat diabetes - was no more effective than placebo for reducing non-alcoholic fatty liver disease (NAFLD).
SMFM releases statement on use of antenatal corticosteroids in late preterm birth period
The Society for Maternal-Fetal Medicine released a statement on the use of antenatal corticosteroids during the late preterm birth period for women at risk of preterm birth.
More Placebo Current Events and Placebo News Articles